Long-term adjuvant ADT improves results of brachy-boost therapy in unfavorable-risk prostate cancer patients

TROG 01.03 RADAR, begun in 2003, was a (partly) randomized clinical trial to help optimize therapy of unfavorable-risk patients.

Neoadjuvant ADT prior to radical surgery in high-risk prostate cancer patients

A group of South Korean researchers have just reported data on the prevalence and outcomes of pT0 disease after neoadjuvant androgen deprivation therapy (ADT) and radical prostatectomy among men receiving first-line therapy for high-risk prostate cancer.

10-year data from RTOG 9910 endorses 8 weeks of neoadjuvant ADT prior to radiation

According to a report on Practice Update last Monday, some interesting data were presented at a plenary session at the annual meeting of the American Society for Radiation Oncology (ASTRO) based on 10-year follow-up of men in the RTOG 9910 trial.

Radiation therapy, neoadjuvant ADT, and initial PSA response

New data from Zelefsky and his colleagues at Memorial Sloan-Kettering Cancer Center suggest that men who respond well to neoadjuvant androgen deprivation therapy (ADT) have better long-term outcomes after radiation therapy given with curative intent for localized prostate cancer.

Immediate, adjuvant ADT after surgery does not significantly affect survival of high-risk men

For many years, physicians at the Mayo Clinic in Rochester, MN, have been offering immediate, adjuvant androgen deprivation therapy (ADT) to some of their surgical patients with more advanced and high-risk forms of prostate cancer. The assumption had been that early use of ADT among such patients might have a significant survival benefit.

Adjuvant ADT after surgery in men with high-risk prostate cancer

Back in June 2010, we reported on the initial results of SWOG 9921 — a trial that randomized 983 men with high-risk features at prostatectomy to receive adjuvant therapy with androgen deprivation (ADT) alone or in combination with mitoxantrone chemotherapy.

6 months of neoadjuvant ADT doubles survival when given with radiation therapy

A new article in Lancet Oncology has reported that a mere 6 months of neoadjuvant hormone therapy, when combined with radiation therapy, cuts the risk of dying from locally advanced prostate cancer by 50 percent compared to radiation alone at 10 years of follow-up.

Limited value of immediate, adjuvant ADT in men with pT3b prostate cancer

New data published by clinical researchers at the Mayo Clinic have suggested that there is no overall survival benefit associated with adjuvant hormone therapy after surgery in men with pathological T3b disease.

A fly in the ointment of RT + adjuvant ADT

Over the years, several randomized trials have shown the benefit of combining androgen deprivation therapy (ADT) with radiation therapy (RT) for the first- and second-line treatment of men with prostate cancer. However,

Immediate adjuvant ADT post surgery: effective but …

The theoretical value of early adjuvant hormone therapy in prolonging survival is known. The practical value to the individual patient, when compared to the side effects and potential adverse consequences (including the cardiovascular adverse event mentioned in the immediately preceding blog post), remains open to considerable question, however. A report in the Journal of Urology addresses […]

Adjuvant mitoxantrone + prednisone + ADT in treatment of high-risk prostate cancer

About 25 years ago the addition of the combination of mitoxantrone + prednisone to androgen deprivation therapy (ADT) was the first form of chemotherapy ever approved for the treatment of metastatic, castration-resistant prostate cancer.

Over-use of neoadjuvant and concurrent ADT in combination with radiation therapy

As anyone who has had long-term androgen deprivation therapy is well aware, this type of treatment may be able to delay the onset or relieve the metastases and bone pain associated with progressive prostate cancer, but it is far from being benign — and comes with a wide spectrum of side effects that affect some […]

Adjuvant radiation + ADT after surgery for SV+ prostate cancer

A new study just published in BJU International offers data suggesting the idea that all men found to have positive seminal vesicles (SV+) after radical prostatectomy should receive immediate adjuvant treatment with external beam radiation and  androgen deprivation therapy (ADT).

Adjuvant and neoadjuvant use of ADT in management of prostate cancer today

The use of androgen deprivation therapy (ADT) alone and in conjunction with other forms of treatment for the management of patients with relatively early stages of prostate cancer (i.e., cancer that is not definitively at least lymph node positive) has been increasingly called into question.

Adjuvant chemotherapy + ADT in high-risk patients after surgery

A number of trials are currently evaluating the potential value of adjuvant chemotherapy after first-line treatment in men with high-risk prostate cancer. The effects of this form of treatment on long-term outcomes still to be established, but …